Form 8-K - Current report:
SEC Accession No. 0001213900-22-055465
Filing Date
2022-09-13
Accepted
2022-09-13 10:47:30
Documents
14
Period of Report
2022-09-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea165680-8k_abvcbio.htm   iXBRL 8-K 24303
2 PRESS RELEASE, DATED SEPTEMBER 13, 2022 ea165680ex99-1_abvcbio.htm EX-99.1 13456
3 SHAREHOLDER LETTER, DATED SEPTEMBER 12, 2022 ea165680ex99-2_abvcbio.htm EX-99.2 9007
  Complete submission text file 0001213900-22-055465.txt   227207

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20220912.xsd EX-101.SCH 3224
5 XBRL LABEL FILE abvc-20220912_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE abvc-20220912_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT ea165680-8k_abvcbio_htm.xml XML 3494
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 221239999
SIC: 2834 Pharmaceutical Preparations